Published in Nucleic Acid Ther on October 18, 2016
Aptamer Cell-Based Selection: Overview and Advances. Biomedicines (2017) 0.75
SH3GLB2/endophilin B2 regulates lung homeostasis and recovery from severe influenza A virus infection. Sci Rep (2017) 0.75
Effective Encapsulation and Biological Activity of Phosphorylated Chemotherapeutics in Calcium Phosphosilicate Nanoparticles for the Treatment of Pancreatic Cancer. Nanomedicine (2017) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (1994) 6.11
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol (2013) 3.39
Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev (2008) 2.87
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
Cholecystokinin and gastrin receptors. Physiol Rev (2006) 1.96
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano (2011) 1.63
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids (2014) 1.49
Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol (1995) 1.09
Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol (1996) 1.06
Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging (2011) 1.02
Aptamers and aptamer targeted delivery. RNA Biol (2009) 1.00
CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med (2005) 0.99
Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer (2000) 0.99
Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano (2010) 0.99
Minimal primer and primer-free SELEX protocols for selection of aptamers from random DNA libraries. Biotechniques (2008) 0.95
Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther (2008) 0.95
Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.94
Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Aptamers and their applications in nanomedicine. Small (2015) 0.88
Targeting a G-protein-coupled receptor overexpressed in endocrine tumors by magnetic nanoparticles to induce cell death. ACS Nano (2014) 0.87
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther (2012) 0.87
Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist. J Am Chem Soc (2013) 0.87
Selective uptake and imaging of aptamer- and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer. ACS Nano (2014) 0.87
Optimization of the enhanced permeability and retention effect for near-infrared imaging of solid tumors with indocyanine green. Am J Nucl Med Mol Imaging (2015) 0.86
Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Int J Oncol (2012) 0.86
Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin. Regul Pept (2007) 0.84
Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol (2014) 0.84
Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics (2015) 0.84
Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv (2012) 0.84
Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. Biomaterials (2013) 0.83
Molecular Recognition of Human Liver Cancer Cells Using DNA Aptamers Generated via Cell-SELEX. PLoS One (2015) 0.82
Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. Theranostics (2015) 0.81
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas (2014) 0.79
Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers. J Nucl Med (2014) 0.78
Potential of the gastric motility drug lorglumide in prostate cancer imaging. Eur J Pharm Sci (2011) 0.76